A. Sureda

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

M. Filetti, R. Salazar, A. Maconi, 2022, European Journal of Cancer.

CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach.

M. Jerkeman, P. Corradini, A. Viardot, 2023, The Lancet. Haematology.

Second Line Treatment of DLBCL: Evolution of Options

A. Mussetti, N. Fabbri, A. Mussetti, 2023, Seminars in Hematology.

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

H. Johnsen, M. Terol, M. Pérez‐Andrés, 2011, Leukemia.

Prior immune checkpoint inhibitor (ICI) therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.

L. Rimassa, A. Cortellini, D. Pinato, 2023, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry.

R. Salazar, F. Mazzoni, N. Harbeck, 2021, JAMA oncology.

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

A. Oriol, B. Paiva, J. San-Miguel, 2024, Haematologica.